NCT05113940 - A Study of PF-07258669 In Healthy Adult Participants | Biotech Hunter

Enrollment

120

Participants

Timeline

Start Date

November 8, 2021

Primary Completion Date

July 27, 2023

Study Completion Date

July 27, 2023

Conditions

Healthy Participants

Interventions

DRUG

PF-07258669

PF-07258669 will be administered as tablets; every 8 hour (Q8H) or every 12 hour (Q12H) over 14 days

DRUG

Placebo

Placebo will be administered as tablets; Q8H or Q12H over 14 days

DRUG

Midazolam

Single doses of Midazolam will be administered as oral solution alone and in combination with PF-07258669

Trial Locations (1)

Pfizer Clinical Research Unit - Brussels, Brussels